[go: up one dir, main page]

MX2014006762A - Metodos para el tratamiento de desordenes cardiovasculares. - Google Patents

Metodos para el tratamiento de desordenes cardiovasculares.

Info

Publication number
MX2014006762A
MX2014006762A MX2014006762A MX2014006762A MX2014006762A MX 2014006762 A MX2014006762 A MX 2014006762A MX 2014006762 A MX2014006762 A MX 2014006762A MX 2014006762 A MX2014006762 A MX 2014006762A MX 2014006762 A MX2014006762 A MX 2014006762A
Authority
MX
Mexico
Prior art keywords
methods
cardiovascular disorder
treating cardiovascular
dosage form
metoprolol
Prior art date
Application number
MX2014006762A
Other languages
English (en)
Inventor
Amit Gupta
Girish Kumar Jain
Mandar Kodgule
Premchand Nakhat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2014006762A publication Critical patent/MX2014006762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una forma de dosificación farmacéutica, terapéuticamente sinérgica de una dosis diaria para el tratamiento de desórdenes cardiovasculares, en donde la forma de dosificación comprende una combinación a dosis fija de metoprolol en forma de liberación prolongada y uno o más agentes antiplaquetarios junto con uno o más excipientes de control de velocidad.
MX2014006762A 2011-12-09 2012-11-01 Metodos para el tratamiento de desordenes cardiovasculares. MX2014006762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3481MU2011 2011-12-09
PCT/IB2012/056084 WO2013084089A1 (en) 2011-12-09 2012-11-01 Methods for treating cardiovascular disorder

Publications (1)

Publication Number Publication Date
MX2014006762A true MX2014006762A (es) 2015-02-10

Family

ID=47501380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006762A MX2014006762A (es) 2011-12-09 2012-11-01 Metodos para el tratamiento de desordenes cardiovasculares.

Country Status (12)

Country Link
US (1) US20140329781A1 (es)
EP (1) EP2841061A1 (es)
JP (1) JP5911969B2 (es)
KR (1) KR20140101391A (es)
CN (1) CN104114163A (es)
AU (1) AU2012349771A1 (es)
BR (1) BR112014013924A2 (es)
CA (1) CA2858522A1 (es)
MX (1) MX2014006762A (es)
RU (1) RU2014127884A (es)
WO (1) WO2013084089A1 (es)
ZA (1) ZA201404422B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520164B (zh) * 2013-10-30 2015-01-28 程刚 一种替卡格雷缓释制剂
WO2015110952A1 (en) * 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
KR101648740B1 (ko) * 2014-09-04 2016-08-17 경상대학교산학협력단 실로스타졸을 유효성분으로 포함하는 독소루비신에 의한 심부전 또는 확장성 심근병증의 예방용 약학 조성물
LT3265126T (lt) 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
US20220160658A1 (en) 2019-01-07 2022-05-26 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients
KR102412252B1 (ko) * 2019-11-07 2022-06-23 서울대학교산학협력단 인덴 n-옥시드 유도체를 포함하는 혈전성 질환의 예방 또는 치료용 약학 조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
WO2021214233A1 (en) 2020-04-22 2021-10-28 Saniona A/S Treatment of hypothalamic obesity
CN115212180B (zh) * 2022-09-03 2024-05-10 深圳市信宜特科技有限公司 一种阿司匹林和硫酸氢氯吡格雷的复方制剂及其制备方法
CN117045610B (zh) * 2023-08-24 2024-04-30 杭州沐源生物医药科技有限公司 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE218467C (es)
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IE64128B1 (en) * 1990-02-26 1995-07-12 Byrne Rynne Holdings Ltd A pharmaceutical composition
US20040198839A1 (en) * 2000-08-23 2004-10-07 Dean Herbert M. Cardioprotective dosage units
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
WO2005084636A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited A process for the preparation of controlled-release pharmaceutical composition of metoprolol
BRPI0611626A2 (pt) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
CN1824312A (zh) * 2005-12-19 2006-08-30 张士东 一种预防和治疗心脑血管疾病复方药及其应用
RU2470636C2 (ru) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
WO2008146178A2 (en) * 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
EP2255797A4 (en) * 2008-02-22 2011-09-07 Hanall Biopharma Co Ltd COMPOSITE PREPARATION
US20100261684A1 (en) * 2009-04-13 2010-10-14 Jacques Benoit Pharmaceutical combination of medication to be used by patients presenting with an acute coronary syndrome so as to stop the process and prevent a myocardial infarction

Also Published As

Publication number Publication date
CA2858522A1 (en) 2013-06-13
KR20140101391A (ko) 2014-08-19
BR112014013924A8 (pt) 2017-06-13
EP2841061A1 (en) 2015-03-04
JP2015500276A (ja) 2015-01-05
US20140329781A1 (en) 2014-11-06
WO2013084089A1 (en) 2013-06-13
RU2014127884A (ru) 2016-02-10
ZA201404422B (en) 2016-01-27
JP5911969B2 (ja) 2016-04-27
NZ625998A (en) 2015-10-30
CN104114163A (zh) 2014-10-22
AU2012349771A1 (en) 2014-07-03
BR112014013924A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
SG10201903119QA (en) Polypeptide vaccine
GB201118656D0 (en) New compounds
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
MX2013011655A (es) Forma de dosis unitaria para administracion oral.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2014005715A (es) N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX2015007280A (es) Terapia de combinacion para cancer.
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
GB201115977D0 (en) Neurodevelopmental disorders